Ifosfamide-based combination chemotherapy in advanced soft-tissue sarcoma: a practice guideline (Q34581983)

3 August 2017

title

Ifosfamide-based combination chemotherapy in advanced soft-tissue sarcoma: a practice guideline (English)

1 reference

3 August 2017

1 reference

Verma S

1

1 reference

3 August 2017

Younus J

2

1 reference

3 August 2017

Stys-Norman D

3

1 reference

3 August 2017

Haynes AE

4

1 reference

3 August 2017

Blackstein M

5

1 reference

3 August 2017

publication date

1 August 2007

1 reference

3 August 2017

1 reference

3 August 2017

volume

14

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

144-148

1 reference

Creative Commons Attribution 4.0 International

3 August 2017

copyright license

start time

1 August 2007

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948866

Phase II evaluation of doxorubicin, ifosfamide, and dacarbazine plus amphotericin B in the treatment of metastatic soft tissue sarcomas. A pilot study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948866

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948866

Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948866

The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948866

Pulmonary metastasectomy for soft tissue sarcomas: is it justified?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948866

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948866

High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948866

A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948866

Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948866

Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948866

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948866

The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948866

Epirubicin and ifosfamide in advanced soft tissue sarcomas

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1948866

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas

27 October 2018

1 reference

12 December 2020

High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma

1 reference

12 December 2020

Low dose adriamycin and ifosfamide in the treatment of advanced adult soft tissue sarcomas

1 reference

12 December 2020

Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas

1 reference

12 December 2020

Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma

1 reference

12 December 2020

Phase II study of ifosfamide-etoposide-mesna in adults with advanced nonosseous sarcomas

1 reference

12 December 2020

Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial

1 reference

12 December 2020

Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma

1 reference

12 December 2020

Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group

1 reference

12 December 2020

Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma

1 reference

12 December 2020

Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study

1 reference

12 December 2020

Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas

1 reference

12 December 2020

Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study

1 reference

12 December 2020

Combination of 5-fluorouracil, adriamycin, ifosfamide and cisplatin in metastatic adult soft tissue sarcoma: results of a phase II study

1 reference

12 December 2020

Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian sarcoma group phase II study

1 reference

12 December 2020

Treatment of advanced refractory sarcomas with ifosfamide and etoposide combination chemotherapy

1 reference

12 December 2020

Identifiers

DOI

10.3747/CO.2007.130

1 reference

3 August 2017

1 reference

3 August 2017

1 reference